Know Cancer

or
forgot password

The CALGB Lung Cancer Tissue Bank


N/A
18 Years
N/A
Open (Enrolling)
Both
Lung Cancer

Thank you

Trial Information

The CALGB Lung Cancer Tissue Bank


OBJECTIVES:

- Collect and store frozen specimens of tumor, involved lymph node (when available), and
grossly uninvolved adjacent lung tissues obtained from patients during surgical staging
or resection of lung cancer, for later molecular analysis.

- Collect and store frozen blood samples from these patients, as a source of reference
DNA to assess somatic mutations associated with tumor or preneoplastic "normal" lung
and to assess levels of circulating markers.

- Correlate these analyses with historical, clinical, pathological, and outcome
information.

OUTLINE: Grossly viable tumor and grossly normal lung tissue are identified and removed from
patient surgical specimens and cryopreserved until shipment to the CALGB Lung Cancer Tissue
Bank for future use in research. Blood specimens are obtained pre- or intra-operatively and
shipped immediately to the Tissue Bank.

Patients do not receive the results of the research.

PROJECTED ACCRUAL: Samples from approximately 100 patients per year will be collected for at
least 5 years.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Suspected or histologically confirmed lung cancer

- Undergoing surgical staging or resection of tumor at a CALGB Lung Cancer Tissue
Bank-approved institution

- No concurrent enrollment on clinical study CALG 140203, intraoperative sentinal node
mapping in non-small cell lung cancer

PATIENT CHARACTERISTICS:

- No known infectious disease (e.g., HIV, tuberculosis, or hepatitis B or C)

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Collection and storage of frozen specimens of tumor, involved lymph node (when available), and grossly uninvolved adjacent lung tissues obtained from patients during surgical staging or resection of lung cancer

Safety Issue:

No

Principal Investigator

David J. Sugarbaker, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Dana-Farber/Brigham and Women's Cancer Center

Authority:

Unspecified

Study ID:

CDR0000271323

NCT ID:

NCT00899782

Start Date:

July 2004

Completion Date:

Related Keywords:

  • Lung Cancer
  • non-small cell lung cancer
  • small cell lung cancer
  • Lung Neoplasms

Name

Location

Roswell Park Cancer InstituteBuffalo, New York  14263
CCOP - Christiana Care Health ServicesWilmington, Delaware  19899
Ellis Fischel Cancer Center at University of Missouri - ColumbiaColumbia, Missouri  65203
Veterans Affairs Medical Center - AshevilleAsheville, North Carolina  28805
Fletcher Allen Health Care - University Health Center CampusBurlington, Vermont  05401
SUNY Upstate Medical University HospitalSyracuse, New York  13210
Rhode Island Hospital Comprehensive Cancer CenterProvidence, Rhode Island  02903
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer InstituteBoston, Massachusetts  02115
Masonic Cancer Center at University of MinnesotaMinneapolis, Minnesota  55455
Siteman Cancer Center at Barnes-Jewish Hospital - Saint LouisSt. Louis, Missouri  63110
Cancer Institute of New Jersey at Cooper - VoorheesVoorhees, New Jersey  08043
Allegheny Cancer Center at Allegheny General HospitalPittsburgh, Pennsylvania  15212
Tunnell Cancer Center at Beebe Medical CenterLewes, Delaware  19958
Union Hospital of Cecil CountyElkton MD, Maryland  21921
Dana-Farber/Brigham and Women's Cancer CenterBoston, Massachusetts  02115
Duke Cancer InstituteDurham, North Carolina  27710
Miriam HospitalProvidence, Rhode Island  02906
Alle-Kiski Medical CenterNatrona Heights, Pennsylvania  15065
Forbes Regional HospitalMonroeville, Pennsylvania  15146